Why English? | Reporting CONSORT-DEFINE Dose-Finding Trials Through Dose Range, Escalation, Interim Decisions, Safety, Operating Characteristics and Recommendations

ORIENTATION

What this guide owns

Current fact check

CONSORT-DEFINE was published in 2023 after Delphi, consensus, consultation and pilot-testing work. Its final report checklist contains 40 dose-finding-specific items—21 new and 19 modified—and a separate abstract checklist.

Canonical boundary

This article owns completed reporting of early-phase dose-finding trials. SPIRIT-DEFINE owns protocol content, ACE owns adaptive trial reporting more broadly, and later-phase CONSORT guidance owns comparative effectiveness trials.

Worked example

Every chapter returns to a fictional first-in-human study evaluating five dose levels of a new oral therapy with staggered cohorts, prespecified safety reviews and a later expansion cohort. It is fictional, low-stakes and educational; it does not report a real school, clinical decision or guaranteed outcome.

Warm up with eduKate’s guides to explaining scientific evidence and asking better questions in class.

CHAPTER 1 OF 14

1. Identify the Study as an Early-Phase Dose-Finding Trial

Back to contents

Why this move matters

Name the phase, design, intervention, population and dose-finding purpose in the title and abstract.

Make the dose-decision algorithm visible

Name the phase, design, intervention, population and dose-finding purpose in the title and abstract. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: The abstract identifies a model-assisted first-in-human dose-escalation and expansion trial. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Phase I alone does not reveal the design or decision problem. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Identify the Study as an Early-Phase Dose-Finding Trial”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 2 OF 14

2. State Objectives, Target Population and Development Context

Back to contents

Why this move matters

Describe whether the trial seeks safety, tolerability, pharmacokinetics, pharmacodynamics, activity, a recommended dose or several of these, and for whom.

Make the dose-decision algorithm visible

Describe whether the trial seeks safety, tolerability, pharmacokinetics, pharmacodynamics, activity, a recommended dose or several of these, and for whom. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: The primary objective is to recommend a dose for adults with refractory disease, not to establish comparative efficacy. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

A dose suitable for one population or treatment combination may not transfer to another. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “State Objectives, Target Population and Development Context”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 3 OF 14

3. Describe the Design and Its Statistical Logic

Back to contents

Why this move matters

Name rule-based, model-based or model-assisted methods, assumptions, target toxicity or other criterion and how accumulating data enter decisions.

Make the dose-decision algorithm visible

Name rule-based, model-based or model-assisted methods, assumptions, target toxicity or other criterion and how accumulating data enter decisions. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: The method uses a prespecified interval around a target toxicity probability. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

A design name does not substitute for the actual algorithm and parameters. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Describe the Design and Its Statistical Logic”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 4 OF 14

4. Justify Starting Dose, Dose Range and Administration Schedule

Back to contents

Why this move matters

Report evidence supporting the first dose, increments, maximum range, route, frequency and schedule, including preclinical or prior human information.

Make the dose-decision algorithm visible

Report evidence supporting the first dose, increments, maximum range, route, frequency and schedule, including preclinical or prior human information. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: The starting dose follows toxicology and pharmacokinetic evidence with a stated safety margin. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

A cautious starting dose does not guarantee later escalations are appropriate. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Justify Starting Dose, Dose Range and Administration Schedule”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 5 OF 14

5. Define Cohorts, Sentinel Dosing and Observation Windows

Back to contents

Why this move matters

State planned and actual cohort sizes, staggering, sentinel participants, within-participant escalation and minimum observation before review.

Make the dose-decision algorithm visible

State planned and actual cohort sizes, staggering, sentinel participants, within-participant escalation and minimum observation before review. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: Two sentinel participants are observed for seven days before the remainder of each cohort is dosed. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

An observation window shorter than the relevant toxicity period can create premature escalation. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Define Cohorts, Sentinel Dosing and Observation Windows”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 6 OF 14

6. Report Dose-Escalation, De-Escalation and Skipping Rules

Back to contents

Why this move matters

Give all possible actions, thresholds, restrictions, overdose controls and who implements them.

Make the dose-decision algorithm visible

Give all possible actions, thresholds, restrictions, overdose controls and who implements them. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: The next dose may escalate one level, remain, de-escalate or stop; dose skipping is prohibited. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Informal caution may be sensible but must not silently replace the prespecified design. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Report Dose-Escalation, De-Escalation and Skipping Rules”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 7 OF 14

7. Describe Interim Reviews and Decision Authority

Back to contents

Why this move matters

Report review timing, data available, blinding, committees, statistical output, recommendations and departures from the algorithm.

Make the dose-decision algorithm visible

Report review timing, data available, blinding, committees, statistical output, recommendations and departures from the algorithm. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: A safety committee reviews all dose-limiting events and exposure data before each action. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

A committee label does not reveal what evidence it saw or who held authority. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Describe Interim Reviews and Decision Authority”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 8 OF 14

8. Explain Transition Points, Expansion and Stopping

Back to contents

Why this move matters

Define criteria for moving from escalation to expansion, adding schedules or combinations, closing doses and stopping for safety, futility or sufficient information.

Make the dose-decision algorithm visible

Define criteria for moving from escalation to expansion, adding schedules or combinations, closing doses and stopping for safety, futility or sufficient information. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: Expansion begins only after a candidate dose meets prespecified safety and exposure criteria. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Expansion can look confirmatory even when its sample remains exploratory. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Explain Transition Points, Expansion and Stopping”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 9 OF 14

9. Define Safety, Tolerability and Dose-Limiting Events

Back to contents

Why this move matters

Provide event definitions, grading, attribution, assessment window, evaluability, late events and rules for multiple or recurrent events.

Make the dose-decision algorithm visible

Provide event definitions, grading, attribution, assessment window, evaluability, late events and rules for multiple or recurrent events. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: A dose-limiting toxicity is defined by grade, relationship, duration and cycle-one window. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Different windows or attribution rules can change the apparent tolerability of the same dose. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Define Safety, Tolerability and Dose-Limiting Events”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 10 OF 14

10. Report Pharmacokinetic, Pharmacodynamic and Activity Outcomes

Back to contents

Why this move matters

Specify sampling, assays, timing, analysis metrics and how exposure, biological effect and early activity contributed to decisions.

Make the dose-decision algorithm visible

Specify sampling, assays, timing, analysis metrics and how exposure, biological effect and early activity contributed to decisions. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: Exposure and biomarker response are shown by dose alongside safety rather than collapsed into one composite judgement. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

A monotonic dose–response cannot be assumed. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Report Pharmacokinetic, Pharmacodynamic and Activity Outcomes”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 11 OF 14

11. Justify Sample Size and Report Operating Characteristics

Back to contents

Why this move matters

Explain cohort limits, simulation scenarios and performance measures such as correct-dose selection, overdose risk, stopping probabilities and expected sample size.

Make the dose-decision algorithm visible

Explain cohort limits, simulation scenarios and performance measures such as correct-dose selection, overdose risk, stopping probabilities and expected sample size. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: Simulations show performance across several true toxicity curves and accrual patterns. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Operating characteristics depend on scenarios and assumptions chosen before the trial. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Justify Sample Size and Report Operating Characteristics”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 12 OF 14

12. Report Participant Flow, Dose Exposure and Analysis Sets

Back to contents

Why this move matters

Show screening, enrolment, cohorts, dose levels, replacements, evaluability, withdrawals, actual doses and which participants entered each analysis.

Make the dose-decision algorithm visible

Show screening, enrolment, cohorts, dose levels, replacements, evaluability, withdrawals, actual doses and which participants entered each analysis. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: The flow separates assigned dose from received dose and explains replacement after an unevaluable safety window. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Replacing participants can affect both safety information and denominators. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Report Participant Flow, Dose Exposure and Analysis Sets”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 13 OF 14

13. Present Dose-Specific Results and Every Major Adaptation

Back to contents

Why this move matters

Report safety, tolerability, exposure, biomarkers and activity by dose and schedule, with dates and reasons for deviations or amendments.

Make the dose-decision algorithm visible

Report safety, tolerability, exposure, biomarkers and activity by dose and schedule, with dates and reasons for deviations or amendments. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: A formulation change and revised escalation cap are dated, justified and reflected in the participant timeline. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Pooling doses can hide a threshold or non-linear pattern. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Present Dose-Specific Results and Every Major Adaptation”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

CHAPTER 14 OF 14

14. Explain the Recommended Dose or Schedule and Its Uncertainty

Back to contents

Why this move matters

State the selected dose, alternatives considered, evidence and trade-offs, who decided, unresolved uncertainty and what the next trial must test.

Make the dose-decision algorithm visible

State the selected dose, alternatives considered, evidence and trade-offs, who decided, unresolved uncertainty and what the next trial must test. Connect starting dose, cohort size, review timing, escalation or de-escalation rule, stopping rule, transition point and decision authority.

Replay one interim decision

Worked example: The team recommends the lower of two active doses because exposure plateaus while toxicity increases, with confirmation planned. Use only information available at that review and show which prespecified rule produced the next dose action.

Separate observed data from recommendation

Report safety, tolerability, pharmacokinetics, pharmacodynamics and activity by dose, then explain how those streams supported the recommended dose or schedule.

Keep early-phase claims proportionate

Recommended does not mean universally optimal, fully safe or proven effective. A dose-finding report can justify the next development step; it usually cannot establish comparative effectiveness or guarantee that the selected dose is optimal.

Student, parent and career transfer

Make one evidence card for “Explain the Recommended Dose or Schedule and Its Uncertainty”: source location, plain-language meaning, limit and next question. A parent or teacher can ask for one everyday explanation and one specialist explanation; both must preserve the same conditions. This habit supports clinical pharmacology, oncology, drug development, biostatistics, trial operations, regulation, research ethics and medical writing without promising a grade, admission, funding decision or job.

PRACTICE LAB

Build a dose-decision decision trail

Student route

1. Choose one original report inside this guide’s scope.
2. Copy its objective and underline actor, action, context, evidence and intended decision.
3. Draw the specific reasoning chain used in this article.
4. Mark each step reported, inferred, contested or unknown.
5. Rewrite the conclusion so it preserves the narrowest important limitation.

Parent or teacher route

Ask the learner to explain CONSORT-DEFINE’s central reporting method twice: once to a classmate and once to a method specialist. Praise a precise correction and a well-stated unknown; both show disciplined attention to evidence.

Early-career route

Create a one-page CONSORT-DEFINE audit with source link, date checked, scope, method logic, decisive wording, contrary evidence, limit and next action. A colleague should be able to continue without guessing.

Continue with eduKate’s guides to reading course and career information and giving useful feedback in group projects.

USEFUL NEXT READING

Connect this narrow owner to its neighbour

Read the SPIRIT-DEFINE protocol guide for a related but different reader job. Return here when the question is specifically how to report an early dose-finding trial so every interim decision and final recommendation can be followed. This boundary keeps one canonical owner per intent.

For English practice across research, school and career communication, visit the English at work and in public life guide.

FREQUENTLY ASKED QUESTIONS

Questions students and parents often ask

What is CONSORT-DEFINE?

Reporting guidance for completed early-phase dose-finding trials with interim escalation or de-escalation strategies.

How many dose-finding-specific items are there?

Forty: 21 new and 19 modified items.

How is it different from SPIRIT-DEFINE?

SPIRIT-DEFINE plans the protocol; CONSORT-DEFINE reports what happened and what was found.

What are operating characteristics?

Simulation-based performance measures such as correct-dose selection, overdose risk, stopping probability or expected sample size.

Does a recommended dose prove effectiveness?

No. It supports further development and requires later confirmation.

Why report every interim decision?

The final dose path depends on accumulating data, prespecified rules and any justified departures from them.